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Background: Cardioembolic stroke (CES) due to atrial fibrillation (AF) is associated with high stroke mortality. Oral
anticoagulation (OAC) reduces stroke mortality, however, the impact of OAC-administration during hospital stay
post ischemic stroke on mortality is unclear. We determined whether the timing of OAC initiation among other
prognostic factors influenced mortality after CES.
Methods: Within the Ludwigshafen Stroke Study (LuSSt), a prospective population-based stroke register, we
analysed all patients with a first ever ischemic stroke or TIA due to AF from 2006 until 2010. We analysed whether
treatment or non-treatment with OAC and initiation of OAC-therapy during and after hospitalization influenced
stroke mortality within 500 days after stroke/TIA due to AF.
Results: In total 479 patients had a first-ever ischemic stroke (n = 394) or TIA (n = 85) due to AF. One-year mortality
rate was 28.4%. Overall, 252 patients (52.6%) received OAC. In 181 patients (37.8%), OAC treatment was started in
hospital and continued thereafter. Recommendation to start OAC post discharge was given in 110 patients (23.0%)
of whom 71 patients received OAC with VKA (14.8%). No OAC-recommendation was given in 158 patients (33.0%).
In multivariate Cox regression analysis, higher age (HR 1.04; 95% CI 1.02-1.07), coronary artery disease (HR: 1.6; 95% CI
1.1-2.3), higher mRS-score at discharge (HR 1.24; 95% CI 1.09-1.4), and OAC treatment ((no OAC vs started in hospital
(HR: 5.4; 95% CI 2.8-10.5), were independently associated with stroke mortality. OAC-timing did not significantly
influence stroke mortality (started post discharge vs. started in hospital (HR 0.3; 95% CI 0.07-1.4)).
Conclusions: OAC non-treatment is the main predictor for stroke mortality. Although OAC initiation during hospital
stay showed a trend towards higher mortality, early initiation in selected patients is an option as recommendation to
start OAC post hospital was implemented in only 64.5%. This rate might be elevated by implementation of special
intervention programs.
Keywords: Oral anticoagulation, Cardioembolic stroke, Atrial fibrillationBackground
Atrial fibrillation (AF) is the main cause of cardioembolic
stroke (CES), the dominant ischemic stroke subtype in the
elderly [1,2]. Additionally, non-diagnosed AF is likely to be
responsible for many cryptogenic strokes [3]. Prevalence
of AF increases with age and lifetime risk of developing
AF is estimated to be 25% after reaching the age of 40 [4].
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Concomitant to the incidence of AF, incidence of CES is
likely to increase. CES is associated with higher stroke se-
verity and mortality [6,7]. Stroke recurrence is associated
with much worse outcome [6,7]. Early stroke recurrence is
frequent in ischemic stroke due to large artery atheroscler-
osis [8], in contrast, it is less common in CES [8,6]. How-
ever, recurrence risk of CES is highest among stroke
subtypes in the long term [7]. Oral anticoagulation (OAC)
with vitamin K antagonists (VKA) and new oral anticoag-
ulants (NOAC) is effective in primary and secondary
stroke prevention and in reducing mortality [9,10]. Both,d. This is an Open Access article distributed under the terms of the Creative
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hemorrhage (ICH) [11]. As early hemorrhagic transform-
ation occurs in CES in up to 17% within 5 days [12], and
occurence of ICH is reported to be up to 12% [13], timing
of OAC initiation after acute CES is still a controversial
issue and its impact on mortality is not clear.
We hypothesized that initiation of OAC in hospital
after first-ever CES is associated with a significant reduc-
tion on mortality compared to OAC non-treatment and
OAC initiation post discharge. Implementation of OAC
recommendation was additionally analysed.
Methods
The “Ludwigshafen Stroke Study” (LuSSt) is a population-
based, prospective registry of stroke and transient ische-
mic attack (TIA) in the City of Ludwigshafen (Germany),
starting January 1st, 2006. A detailed description of LuSSt
has been published recently [14]. All patients with first-ever
ischemic strokes (FEIS) due to AF until December 31st,
2010 were included in the present analysis.
Summary of study population, case ascertainment
follow-up and standard definitions
Ludwigshafen is an industrial city in the state of Rhineland-
Palatinate in Western Germany. The total source popu-
lation was 167,657 inhabitants (83,009 males and 84,648
females) on December 31st, 2008, which was the midpoint
of the study period. Multiple overlapping methods of pa-
tient identification were used in order to achieve complete
case ascertainment as described before [14]. Collaboration
with all hospitals in Ludwigshafen and surrounding hos-
pitals treating stroke patients outside the city boundaries
ensured complete case acquisition. Patients who have
been treated in other hospitals, hospitals abroad and
non-hospitalized patients were identified by contacting all
general practitioners, specialists in internal medicine and
neurologists practicing in Ludwigshafen. In addition nurs-
ing and residential homes were contacted regularly. In case
of identified stroke patients via death certificate, patients’
general practitioner was contacted in order to achieve more
information, especially with regards to stroke symptoms,
current stroke and antithrombotic treatment. Follow up
investigations were conducted by telephone 28 days, 3, 12
and 36 months after stroke onset, using a standardised
questionnaire, if written informed had been given by patients
or their legal representatives. Information about survival was
collected by population registration authority in all patients
without statement of consent, or if patients could not be
contacted. The study (LuSSt) was approved by the ethics
committee of “Landesärztekammer Rhineland-Palatinate”
(reference number: 837.333.05) and the local data protection
commissioner of Rhineland-Palatinate. Stroke was de-
fined according to the definition of the World Health
Organization (WHO) [15]. Stroke subtype classificationwas based on the results of brain imaging, discriminating
between ischemic stroke (IS), intracerebral hemorrhage
(ICH) or subarachnoid hemorrhage (SAH). Patients with
no clinical evidence of any previous stroke event were
diagnosed as first-ever stroke (FES) irrespective of brain
imaging. Assignment to etiology in ischemic stroke was
performed using modified TOAST-criteria and has been
described in detail before [2]. TIA was defined as a tran-
sient focal cerebral ischemia with symptoms lasting <
24 hours independent of neuroimaging results. Due to
current changes in the definition of TIA by usage of MRI
imaging, we included patients with both, IS and TIA. All
patients admitted to the Klinikum Ludwigshafen received
intensive diagnostic workup as previously described [2].
About 90% of all patients with FES in the source popula-
tion are admitted to this hospital.
Neuroradiological findings, risk factors, risk stratification
scores and stroke severity
Neuroradiological findings were categorized as territor-
ial infarction (TI), lacunar infarction (LI), hemorrhagic
transformation (HT) including hemorrhagic infarction,
defined as petechial bleeding in the infarction area, and
parenchymal hematoma as hematoma in the infarcted
area with a space-occupying effect or a traumatic sub-
arachnoid hemorrhage (SAH) due to ischemic infarc-
tion [12]. Hemorrhagic transformation was detected in
CT/MRI performed on admission or in repeated CT/
MRI performed during hospital stay. Cardiovascular
risk factors were defined according to current national
and international guidelines as recently described in de-
tail [2]. AF (known or new diagnosis) was defined with
current ESC guidelines as irregular RR intervals with a
variable atrial cycle length and absent P waves in the
surface ECG [16]. Other sources of cardiac embolism
have been ruled out by using transthoracic or trans-
esophageal echocardiography. The CHA2DS2-VASc and
HASBLED-Score were used as risk stratification tools to
evaluate stroke and bleeding risk [17]. Stroke severity was
analysed using the National Institute of Health Stroke
Scale (NIHSS) on admission and modified Rankin-Scale
(mRS) on discharge by experienced neurologists of the
study team [18,19]. The glomerular filtration rate was
determined on admission using Modification of Diet in
Renal Disease (MDRD) formula [20].
Antithrombotic treatment
Prestroke treatment with VKA (=oral anticoagulation)
and antiplatelet agents was assessed. In patients receiv-
ing VKA, international normalized ratio (INR) was de-
termined on admission. Poststroke management was
subdivided as follows: 1. No OAC (neither given nor rec-
ommended and OAC recommended but not given post
hospital stay); 2. OAC started in hospital; 3. OAC started
Table 1 Baseline characteristics of 479 patients with AF-associated FE-IS and TIA (neuroimaging, stroke severity and
risk stratification scores)
Variable (N*) Death within 500 days Survival at 500 days p-value univariate p-value multivariate
N (%)
Gender (479*/479) p=0.31
Male 197 (41.1%) 55 (27.9%) 142 (72.1%)
Female 282 (58.9%) 92 (32.6%) 190(67.4%)
Age (years) (479*/479) p<0.0001 p=0.001
20-65 44 (9.2%) 3 (6.8%) 41 (93.2%)
66-75 105 (21.9%) 18 (17.1%) 87 (82.9%)
76-85 204 (42.6%) 56 (27.5%) 148 (72.6%)
>85 126 (26.3%) 70 (55.6%) 56 (44.4%)
Diagnosis (479*/479) p=0.0001 p=0.95
Ischemic stroke 394 (82.3%) 135 (34.3%) 259 (65.7%)
TIA 85 (17.7%) 12 (14.1%) 73 (85.9%)
Neuroradiological Findings (476*/479)
Territorial infarction (recent) 256 (53.8%) 99 (38.7%) 157 (61.3%) p<0.0001 p=0.055
Territorial infarction (old) 45 (9.5%) 15 (33.3%) 30 (66.7%) p=0.61
Hemorrhagic transformation 26 (5.5%) 14 (53.8%) 12 (46.2%) p=0.01 p=0.46
Hemorrhagic infarction 15 (57.7%) 7 (46.7%) 8 (53.3%)
Parenchymal haematoma 8 (30.8%) 6 (75%) 2 (25%)
Subarachnoidal hemmorh. 3 (11.5%) 1 (33.3%) 2 (66.7%)
Stroke severity
NIHSS at admission (461*/479) p<0.0001 p=0.8
0-3 227 (49.2%) 38 (16.7%) 189 (83.3%)
4-8 117 (25.4%) 39 (33.3%) 78 (66.7%)
>9 117 (25.4%) 62 (53%) 55 (47%)
mRS at discharge (470*/479) p<0.0001 p=0.0007
0-1 197 (41.9%) 23 (11.7%) 174 (88.3%)
2-3 123 (26.2%) 38 (30.9%) 85 (69.1%)
>4 150 (31.9%) 85 (56.7%) 65 (43.3%)
Risk stratification score
CHA2DS2-Vasc-Score (452*/479) p=0.0003
2-4 30 (6.6%) 2 (6.7%) 28 (93.3%)
5 93 (20.6%) 23 (24.7) 70 (75.3%)
6 159 (35.2%) 42 (26.4%) 117 (73.6%)
7 95 (21%) 31 (32.6%) 64 (67.4%)
8-9 75 (16.6%) 35 (46.7%) 40 (53.3%)
HASBLED-Score (458*/479) p<0.0001
0-2 115 (25.1%) 18 (15.7%) 97 (84.8%)
3 301 (65.7%) 100 (33.2%) 201 (66.8%)
4 39 (8.5%) 18 (46.2%) 21 (53.6%)
5 3 (0.7%) 2 (66.7%) 1 (33.3%)
*Patients with complete information.
Significant p-values in bold.
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Table 2 Baseline characteristics of 479 patients with AF-associated FE-IS and TIA (risk factors and treatment)
Variable (N*) Death within 500 days Survival of 500 days p-value univariate p-value multivariate
N (%)
Risk factors
CAD (465*/479) 144 (31%) 54 (37.5%) 90 (62.5%) p=0.02 p=0.01
MI (475*/479) 84 (17.7%) 33 (39.3%) 51 (60.7%) p=0.07
Heart failure (452*/479) 169 (37.4%) 62 (36.7%) 107 (63.3%) p=0.01 p=0.94
PAD (461*/479) 48 (10.4%) 23 (47.9%) 25 (52.1%) p=0.004 p=0.13
Hypertension (479*/479) 446 (93.1%) 136 (30.5%) 310 (69.5%) p=0.70
Diabetes (478*/479) 157 (32.8%) 43 (27.4%) 114 (72.6%) p=0.34
Hypercholesterolemia (470*/479) 285 (60.6%) 79 (27.7%) 206 (72.3%) p=0.26
Smoking (400*/479) p=0.24
Nonsmoker 206 (51.5%) 69 (33.5%) 137 (66.5%)
Smoker 42 (10.5%) 11 (26.2%) 31 (73.8%)
Former smoker 152 (38%) 39 (25.7%) 113 (74.3%)
GFR (461*/479) p<0.0001 p=0.09
0-<30 16 (3.5%) 8 (50%) 8 (50%)
30-<60 160 (34.7%) 66 (41.3%) 94 (58.7%)
≥60 285 (61.8%) 65 (22.8%) 220 (77.2%)
Treatment (479*/479)
Intraveneous thrombolysis p=0.62
Yes 47 (9.8%) 16 (34%) 31 (66%)
No 432 (90.2) 131 (30.3) 301 (69.7)
Antithrombotic treatment (479*/479)
OAK prior to stroke 116 (24.2%) 20 (17.2%) 96 (82.8%) p=0.0003 p=0.91
INR <2 65 (58%) 15 (23.1%) 50 (76.9%)
INR ≥2 44 (39.3%) 4 (9.1%) 40 (90.9%)
INR unknown 7 (6%) 1 (14.3%) 6 (85.7%)
Antiplatelets prior to stroke (479*/479) p<0.0001
No antiplatelet 298 (62.2%) 69 (23.2%) 229 (76.8%)
Antiplatelet 181(37.8%) 78 (43.1%) 103 (56.9%)
OAC management post stroke (479*/479) p<0.0001 p<0.0001
No VKA 200 (41.8%) 127 (63.5%) 73 (37.5%)
OAC neither given, nor recommended 158 (79%) 109 (69%) 49 (31%)
OAC recommended, but not given 42 (21%) 18 (42.9%) 24 (57.1%)
VKA started in hospital 181 (37.8%) 16 (8.8%) 165 (91.2%)
VKA started post discharge 71 (14.8%) 2 (2.8%) 69 (97.2%)
Unknown 27 (5.6%) 2 (7.4%) 25 (93.6%)
Recurrent cerebral event (500days) 43/479 (9%) 21 (48.8%) 22 (51.2%) p=0.009 p=0.27
IS 33 (76.7%) 19 (57.6%) 14 (42.4%)
TIA 6 (14%) 0 6
ICH 4 (9.3%) 2 (50%) 2 (50%)
*Patients with complete information.
Significant p-values in bold.
Palm et al. BMC Neurology 2014, 14:199 Page 4 of 8
http://www.biomedcentral.com/1471-2377/14/199
Palm et al. BMC Neurology 2014, 14:199 Page 5 of 8
http://www.biomedcentral.com/1471-2377/14/199post discharge; 4. Unknown. If OAC was started in
hospital or recommended and status post hospital was
unknown, OAC management post stroke was ascertained
unknown. If VKA treatment had not been recommended,
reasons were protocolled. Posthospital treatment with
VKA after 30 days, as well as 3, 12 and 36 month after
stroke were checked. In order to include majority of
patients in univariate and multivariate Cox regression
analysis, vital status was additionally assessed 500 days
after stroke onset. Recurrent stroke, TIA or bleeding were
documented within 500 days after stroke.
Statistical analyses
Χ2-test was used to compare categorical data and fisher
exact test was applied to analyse normally distributed
continuous data in univariate analysis. All variables being
significant except risk stratification scores were then
included in a multivariate Cox regression model followed
by backward elimination of nonsignificant variables (p <
0,05). In order to lower impact of stroke severity on stroke
mortality, patients who died within 7 days after stroke
were excluded for multivariate Cox regression analysis. All
data were analysed using SAS 9.3 software (SAS Institute,
North Carolina, RRID:nif-0000-31484). All tests were
two-sided. Level of significance was set to 5% for all tests.
Results
During study period, 502 patients had a FEIS or TIA due to
AF. ICH was ruled out in all patients by neuroimaging. AsFigure 1 Kaplan-Meier estimate of survival after ischemic stroke acco
7 days (n = 13) excluded).survival status was unknown in 23 patients (4.8%), 479 pa-
tients with FEIS (n = 394) and TIA (n = 85) were finally in-
cluded in the present analysis. Mean age was 79.3 years +/−
10.1 (women: 80.7 years +/− 10.5; men: 77.4 years +/− 9.1).
Median of hospital stay was 10.8 days (range 1–35 days).
332 patients (69.3%) were initially admitted to a stroke unit,
whereas 29 patients (6.1%) received intensive care treat-
ment. Overall, 18 patients (3.8%) were treated ambulatory.
Thirteen patients died within first week. One year mortality
rate was 28.4% and mortality rate after 500 days was 30.7%.
Neuroimaging was performed in all patients with 106
patients (22.1%) receiving cranial MRI. AF was newly
diagnosed in 62 (12.9%) patients. Acute ischemic tissue
damage could be observed in 20 patients (23.5%) with TIA
based on neuroimaging. Due to study period, no patient
received NOAC treatment. Baseline characteristics of all
patients are displayed in Tables 1 and 2. Overall, OAC
with VKA was started in hospital in 184 patients and it
was continued post hospital in 181 patients (98.4%).
Starting OAC post discharge was recommended in total in
130 patients. In 20 out of these patients OAC status post
discharge was unknown and OAC-recommendation was
implemented in 71 patients (64.5%). Figure 1 shows Kaplan-
Meier estimate of survival after ischemic stroke according
to OAC management. Antiplatelet therapy was prescribed
in 173 (36.1%) patients. There was no patient who re-
ceived a combination of OAC and antiplatelet agent. Main
reasons for non-OAC recommendation were bad general
condition (28%, n = 41), risk of falling (27%, n = 39) andrding to OAC management ((n = 439) patients who died within
Table 3 Multivariate Cox regression analysis
Variable HR (95% CI) P-value
Model A n = 397 (90.4%)
Age (per year) 1.04 (1.02-1.07) p = 0.001
CAD (Yes vs. No) 1.6 (1.1-2.3) p = 0.01
mRS at discharge (per year) 1.2 (1.1-1.4) p = 0.0007
OAK management post stroke
(VKA in hospital as reference)
No VKA 5.4 (2.8-10.5) p < 0.0001
VKA (started post discharge) 0.3 (0.07-1.4) p = 0.1
Significant p-values in bold.
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with recommendation to start OAC treatment post dis-
charge, patients receiving OAC treatment in hospital had
signficant lower initial stroke severity as indicated by
NIHSS (p > 0.0001), lower HASBLED-score (p = 0.001),
less signs of hemorrhagic transformation (p = 0.002) and
territorial infarction (p > 0.0001), high rate of premedica-
tion withVKA (p < 0.0001), low rate of premedication with
antiplatelets (p < 0.0001) and significant lower mRS-score
(p < 0.0001) on discharge. Recurrent stroke within 500 days
occurred in 43 patients (9%) with 13 patients (30,2%)
being on OAC (started in hospital: n = 8 (61.5%) vs. started
post discharge: n = 5 (38.5%), of which 6 patients (46.1%)
had an INR-value below 2. Three out of 5 patients (60%)
with OAC having an INR > 2, had a recurrent ischemic
stroke within 30 days after OAC. One year recurrence rate
was 7.1% (n = 34), whereas rate of early stroke recurrenceFigure 2 Kaplan-Meier estimate of survival after ischemic stroke accowithin 14 days was 0.8% (n = 4) and within 7 days 0.4%
(n = 2). OAC associated ICH was observed in three
patients (0.6%), two (66.7%) occuring within 30 days
after initial event.
Results of Cox regression analysis are displayed in Table 3.
Higher age, higher mRS-score at discharge, diagnosis of
CAD, and OAC treatment post stroke were independently
associated with stroke mortality. Figure 2 additionally pre-
sents Kaplan-Meier estimate of survival with regard to
stroke recurrence. Poststroke survival was highest in those
patients receiving OAC irrespective of stroke recurrence.
Discussion
We analysed impact of risk factors on mortality
(500 days) in patients after first ever AF-associated CES
or TIA in a population based stroke registry (LuSSt)
particulary with regards to the effect of different OAC
timings after FEIS. One-year mortality rate was 28.4%,
which is in line with former study reports, where pa-
tients having a stroke associated with AF had a high risk
of death in the year after FEIS [21].
Our data show that OAC non-treatment after AF-
associated ischemic stroke is the main predictor for
stroke mortality. Mortality was 5.4 times higher in
patients not receiving OAC as compared to those that
already received OAC in hospital. This fact again under-
lines the need for OAC treatment after CES [22]. Alarm-
ingly, OAC-recommendation was only implemented in
71 out of 110 patients calling for improvement in
outpatient care (e.g. by the implementation of specialrding to recurrence of stroke on and off OAC treatment (n = 479).
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http://www.biomedcentral.com/1471-2377/14/199interventional programs) [23]. Interestingly, OAC initiation
post discharge showed a trend (p = 0.1) towards lower mor-
tality as compared to those that received OAC in hospital
(HR 0.3; 95% CI 0.07-1.4) in multivariate analysis. Increased
risk of bleeding under early treatment with OAC in more
severe strokes might be one explanation [24]. Increased risk
of ischemic stroke during first 30 days of treatment might
also partly account for this [25]. In addition to OAC treat-
ment, we found higher age and a higher mRS-score at
discharge as independent predictors of mortality after CES.
Recent data from the Canadian Stroke Network demon-
strated association between older age and worse outcome
after CES. Interestingly, there was no such association in
those patients receiving therapeutic OAC treatment prior
to stroke emphasizing the importance of OAC treatment in
older patients [26]. It is well known that myocardial infarc-
tion is the leading cause of death in patients with cerebro-
vascular diseases [27]. We found CAD to be independently
associated with mortality after CES. Antiplatelet agents
such as Aspirin or Clopidogrel have shown to reduce ische-
mic events in patients with CAD [28]. Unfortunately, con-
comitant use of antiplatelet agents and OAC subsequently
increases risk of bleeding [29]. Randomized trials have
shown VKA to be as effective as a combination of VKA
and Aspirin and more effective as Aspirin alone in CAD
patients considering myocardial infarction [30]. Although
recent observational studies showed decreased rate of
MI in AF patients receiving Dabigatran as compared to
Warfarin [31], certain subgroup analyses and metanalyses
of randomized controlled trials demonstrated an increase
of myocardial infarction [32,33]. However, data of end-
point driven randomized controlled trials on NOACs are
missing. Right now, OAC with VKA might remain import-
ant for CES patients having CAD. Recurrence rates were
similar to those reported in previous trials [34,35]. Al-
though being limited by small sample size, stroke recur-
rence did not influence survival in those patients receiving
OAC, whereas there was a clear interaction in those
patients that did not receive OAC. Clinical benefit of OAC
in AF is again underlined.
Our study has strengths and limitations. Being based on
registry data, study design was primarily descriptive and
besides other confounding factors, quality of treatment of
risk factors was not implemented, especially considering
time of therapeutic range of VKA treatment. Furthermore
we only analysed all-cause mortality. However, LuSSt is a
population-based stroke registry without any age restric-
tions. Multiple overlapping methods were used to ensure
nearly complete case ascertainment and high case com-
pleteness was achieved with regard to stroke mortality.
Conclusion
In our study OAC non-treatment was the main pre-
dictor for mortality after FEIS. A later initiation of OACtreatment post hospital was not inferior to early initi-
ation during hospital stay, however, one third of those
patients who were recommended to be treated with
OACs never received treatment. Special secondary pre-
ventive programs may increase the proportion of antic-
oagulated patients after stroke due to AF.
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